Number 3 - MARCH 2005
COLORECTAL CANCER - MOLECULAR BIOLOGY

Xiong B, Sun TJ, Hu WD, Cheng FL, Mao M, Zhou YF. Expression of cyclooxygenase-2 in colorectal cancer and its clinical significance. World J Gastroenterol. 2005 Feb 28;11(8):1105-8.  

Yao M, Zhou W, Sangha S, Albert A, Chang AJ, Liu TC, Wolfe MM. Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer. Clin Cancer Res. 2005 Feb 15;11(4):1618-28. 

Ericson K, Nilbert M, Bladstrom A, Anderson H, Olsson H, Planck M. Familial risk of tumors associated with hereditary non-polyposis colorectal cancer: a Swedish population-based study. Scand J Gastroenterol. 2004 Dec;39(12):1259-65. 

Boxer GM, Tsiompanou E, Levine T, Watson R, Begent RH. Immunohistochemical Expression of Vascular Endothelial Growth Factor and Microvessel Counting as Prognostic Indicators in Node-Negative Colorectal Cancer.
Tumour Biol. 2005 Feb 28;26(1):1-8 

Chiu ST, Hsieh FJ, Chen SW, Chen CL, Shu HF, Li H. Clinicopathologic Correlation of Up-regulated Genes Identified Using cDNA Microarray and Real-time Reverse Transcription-PCR in Human Colorectal Cancer.
Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):437-43.  

Losi L, Baisse B, Bouzourene H, Benhattar J. Evolution of intratumoral genetic heterogeneity during colorectal cancer progression. Carcinogenesis. 2005 Feb 24;  

Vidaurreta M, Sanz-Casla MT, Maestro ML, Rafael S, Jimenez F, Arroyo M, Fernandez C, Cerdan J.  [Microsatellite instability predicts better outcome in colorectal cancer patients.] Med Clin (Barc). 2005 Feb 5;124(4):121-5. Spanish.  

Lenhard K, Bommer GT, Asutay S, Schauer R, Brabletz T, Goke B, Lamerz R, Kolligs FT. Analysis of promoter methylation in stool: a novel method for the detection of colorectal cancer. Clin Gastroenterol Hepatol. 2005 Feb;3(2):142-9.  

Zinzindohoue F, Lecomte T, Ferraz JM, Houllier AM, Cugnenc PH, Berger A, Blons H, Laurent-Puig P. Prognostic significance of MMP-1 and MMP-3 functional promoter polymorphisms in colorectal cancer. Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):594-9. 

Slattery ML, Murtaugh M, Caan B, Ma KN, Neuhausen S, Samowitz W. Energy balance, insulin-related genes and risk of colon and rectal cancer. Int J Cancer. 2005 Feb 1;  

Ripa RS, Katballe N, Wikman FP, Jager AC, Bernstein I, Orntoft T, Schwartz M, Nielsen FC, Bisgaard ML. Presymptomatic diagnosis using a deletion of a single codon in families with hereditary non-polyposis colorectal cancer. Mutat Res. 2005 Feb 15;570(1):89-96.  

Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, Hamilton A, Pan D, Schrag D, Schwartz L, Klimstra DS, Fridman D, Kelsen DP, Saltz LB. Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry. J Clin Oncol. 2005 Jan 27;  

Peeters CF, de Geus LF, Westphal JR, de Waal RM, Ruiter DJ, Wobbes T, Oyen WJ, Ruers TJ. Decrease in circulating anti-angiogenic factors (angiostatin and endostatin) after surgical removal of primary colorectal carcinoma coincides with increased metabolic activity of liver metastases. Surgery. 2005 Feb;137(2):246-9.  

Arrigoni A, Sprujevnik T, Alvisi V, Rossi A, Ricci G, Pennazio M, Spandre M, Cavallero M, Bertone A, Foco A, Rossini FP. Clinical identification and long-term surveillance of 22 hereditary non-polyposis colon cancer Italian families. Eur J Gastroenterol Hepatol. 2005 Feb;17(2):213-9.  

Munro AJ, Lain S, Lane DP. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer. 2005 Feb 14;92(3):434-44. 

Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis.
J Clin Oncol. 2005 Jan 20;23(3):609-18. Review 

Fernandes LC, Kim SB, Matos D. Cytokeratins and carcinoembryonic antigen in diagnosis, staging and prognosis of colorectal adenocarcinoma. World J Gastroenterol. 2005 Feb 7;11(5):645-8.  

Anacleto C, Rossi B, Lopes A, Soares FA, Rocha JC, Caballero O, Camargo AA, Simpson AJ, Pena SD. Development and application of a multiplex PCR procedure for the detection of DNA methylation in colorectal cancer. Oncol Rep. 2005 Feb;13(2):325-8.  

Yoshino M, Ishiwata T, Watanabe M, Komine O, Shibuya T, Tokunaga A, Naito Z. Keratinocyte growth factor receptor expression in normal colorectal epithelial cells and differentiated type of colorectal cancer. Oncol Rep. 2005 Feb;13(2):247-52. 

Yang J, Liu FX, Yan XC, He GY, Liu LM.  [Clinical significance of survivin expression in colorectal cancer and its relationship with cell apoptosis and angiogenesis.] Ai Zheng. 2005 Jan;24(1):116-20. Chinese. 

Soumaoro LT, Uetake H, Higuchi T, Takagi Y, Enomoto M, Sugihara K. Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res. 2004 Dec 15;10(24):8465-71. 

Yao HB, Wu AG, Huang ZH.  [Expression of survivin and its clinical significance in colorectal carcinoma.] Di Yi Jun Yi Da Xue Xue Bao. 2004 Dec;24(12):1412-5. Chinese. 

 Spano JP, Lagorce C, Atlan D, Milano G, Domont J, Benamouzig R, Attar A, Benichou J, Martin A, Morere JF, Raphael M, Penault-Llorca F, Breau JL, Fagard R, Khayat D, Wind P. Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol. 2005 Jan;16(1):102-8.  

Langenskiold M, Holmdahl L, Falk P, Ivarsson ML. Increased plasma MMP-2 protein expression in lymph node-positive patients with colorectal cancer. Int J Colorectal Dis. 2004 Dec 8;  

Saito N, Kameoka S. Serum laminin is an independent prognostic factor in colorectal cancer. Int J Colorectal Dis. 2004 Dec 8; 

Wright CM, Dent OF, Newland RC, Barker M, Chapuis PH, Bokey EL, Young JP, Leggett BA, Jass JR, Macdonald GA. Low level microsatellite instability may be associated with reduced cancer specific survival in sporadic stage C colorectal carcinoma. Gut. 2005 Jan;54(1):103-8. 

Chapusot C, Martin L, Puig PL, Ponnelle T, Cheynel N, Bouvier AM, Rageot D, Roignot P, Rat P, Faivre J, Piard F.  What is the best way to assess microsatellite instability status in colorectal cancer? Study on a population base of 462 colorectal cancers. Am J Surg Pathol. 2004 Dec;28(12):1553-9.  

Raut CP, Pawlik TM, Rodriguez-Bigas MA. Clinicopathologic features in colorectal cancer patients with microsatellite instability. Mutat Res. 2004 Dec 21;568(2):275-82.  

Dundas SR, Lawrie LC, Rooney PH, Murray GI. Mortalin is over-expressed by colorectal adenocarcinomas and correlates with poor survival. J Pathol. 2005 Jan;205(1):74-81.  

Brennetot C, Buhard O, Jourdan F, Flejou JF, Duval A, Hamelin R. Mononucleotide repeats BAT-26 and BAT-25 accurately detect MSI-H tumors and predict tumor content: implications for population screening. Int J Cancer. 2005 Jan 20;113(3):446-50.  

Chang SC, Lin JK, Lin TC, Liang WY. Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma.
Int J Oncol. 2005 Jan;26(1):65-75.   

Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005 Feb 10;23(5):1011-27.